drugsJanuary 16, 2020
Tag: AI , Prostate Cancer , prostate needle biopsy
An artificial intelligence (AI) system can be used to detect and grade prostate cancer in prostate needle biopsy samples, according to a study published online January in The Lancet Oncology.
Peter Ström, from the Karolinska Institutet in Stockholm, and colleagues used 6,682 slides from needle core biopsies from 976 participants in a Swedish population-based study (STHLM3) and 271 slides from 93 men from outside the study to train deep neural networks for prostate biopsy assessment. The networks were evaluated using an independent data set with 1,631 biopsies from 246 men from STHLM3 and an external validation set of 330 biopsies from 73 men. Grading performance was assessed on 87 biopsies graded by 23 experienced urological pathologists.
The researchers found that on the independent and external validation data sets, AI achieved an area under the receiver operating characteristics curve (AUC) of 0.997 and 0.986, respectively, for distinguishing between benign and malignant biopsy cores. The association between cancer length predicted by the AI and assigned by the reporting pathologist was 0.96 and 0.87 for the independent data set and the external validation data set, respectively. The AI system achieved a mean pairwise kappa of 0.62 for assigning Gleason grades; this value was within the range of the corresponding values for the expert pathologists (0.60 to 0.73).
"Our results show that it is possible to train an AI system to detect and grade prostate cancer on the same level as leading experts," a coauthor said in a statement.
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: